Anthony Marucci, Celldex CEO

Tak­ing aim at Xo­lair, Celldex of­fers a pos­i­tive ear­ly read­out for their ri­val drug — but re­searchers have a lot of work re­main­ing

The re­searchers at Celldex are flag­ging some pos­i­tive da­ta from a small ear­ly stage tri­al for their drug bar­zolvolimab in pa­tients with mod­er­ate to se­vere …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.